Biogen starts phase 1/2 clinical study of ISIS-SOD1 Rx in ALS patients
Isis Pharmaceuticals' partner Biogen has started a Phase 1/2 clinical study of ISIS-SOD1Rx (BIIB067) in patients with amyotrophic lateral sclerosis (ALS).
Patients with ALS fatal neurodegenerative disorder suffer progressive degeneration of the motor neurons, which leads to a declining quality of life and even could lead to death.
Click on this link for more information.
